Cyprus-based biotechnology company iDNA Genomics Public Ltd on Monday announced that it approved its audited consolidated financial statements for 2025, reporting a wider loss and a sharp deterioration in its balance sheet compared with the previous year.
The company’s board approved its annual report and audited consolidated financial statements for the year ended December 31, 2025, prepared in accordance with applicable legislation and accounting standards.
The report includes the consolidated
